Advertisement
Advertisement
Simulect

Simulect

basiliximab

Manufacturer:

Novartis

Distributor:

DKSH
Concise Prescribing Info
Contents
Basiliximab
Indications/Uses
Prophylaxis of acute organ rejection in de novo renal transplantation in combination w/ ciclosporin & corticosteroid-based immunosuppression in adults & childn; or long-term immunosuppressive triple therapy w/ ciclosporin, corticosteroids & either azathioprine or mycophenolate mofetil in adults.
Dosage/Direction for Use
2 doses: 1st dose w/in 2 hr before transplantation surgery & 2nd dose 4 days after transplantation. Adult & childn ≥35 kg 20 mg/dose; <35 kg 10 mg/dose.
Contraindications
Special Precautions
Discontinue use if severe hypersensitivity reactions occur. Increased risk of developing lymphoproliferative disorders & opportunistic infections eg, cytomegalovirus. Not recommended w/ live vaccines for immunosuppressed patients. Women of childbearing potential should use effective contraception for 4 mth after last dose. Pregnancy. Not to be used during lactation & for 4 mth after last dose.
Adverse Reactions
Constipation, UTI, HTN, URTI. Adults: Pain, nausea, peripheral oedema, anaemia, headache, hyperkalaemia, hypercholesterolaemia, post-op wound complication, increased wt & blood creatinine, hypophosphataemia, diarrhoea. Ped: Hypertrichosis, rhinitis, pyrexia, viral infection, sepsis.
MIMS Class
Immunosuppressants
ATC Classification
L04AC02 - basiliximab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.
Presentation/Packing
Form
Simulect powd for inj/infusion (vial) 20 mg
Packing/Price
1's
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement